E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Refractory Colorectal Cancer |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10061451 |
E.1.2 | Term | Colorectal cancer |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Primary Objective Part 1 • Evaluate the safety of escalating dose of zalutumumab in combination with irinotecan in patients with colorectal cancer (CRC) who have failed previous standard chemotherapy and who have progressed during or within 6 months of stopping treatment with cetuximab. Part 2 • To investigate the efficacy of zalutumumab administered alone or in combination with irinotecan in patients with CRC who have failed previous standard chemotherapy and who have progressed during or within 6 months of stopping treatment with cetuximab. |
|
E.2.2 | Secondary objectives of the trial |
Secondary Objective • To determine the pharmacokinetic profile of zalutumumab administered alone or in combination with irinotecan • To evaluate potential biomarkers.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Males and Females age ≥ 18 years. 2. Following receipt of verbal and written information about the study, the patient must provide signed informed consent before any study related activity is carried out. 3. Histologically or cytologically confirmed diagnosis of CRC. 4. Documented disease progression (verified by CT scan and/or MRI according to RECIST) during or within 6 months of finishing cetuximab-based therapy • These images can be used as baseline for this protocol provided they were taken no more than 3 weeks prior to randomization 5. The cumulative dose of cetuximab must be ≥ 1000mg/m2 6. Failure and/or intolerance to standard chemotherapy 7. Measurable disease defined as one or more target lesions according to RECIST. 8. WHO performance status ≤ 2. 9. Absence of KRAS mutation in the tumor specimen.
|
|
E.4 | Principal exclusion criteria |
1. Prior treatment with anti-EGFR antibodies other than cetuximab 2. Received the following treatments within 4 weeks prior to Visit 2: - Cytotoxic or cytostatic anti-cancer chemotherapy - Total resection or irradiation of the target lesion - Any investigational agent 3. Diarrhea CTCAE > 1 4. Skin rash CTCAE > 1 5. Intolerance to irinotecan 6. Past or current malignancy other than CRC, except for: - Cervical carcinoma Stage 1B or less - Non-invasive basal cell and squamous cell skin carcinoma - Malignant melanoma with a complete response of a duration of > 10 years - Other cancer diagnoses considered in remission for > 5 years 7. Chronic or current infectious disease 8. Known brain metastasis or leptomeningeal disease. 9. Clinically significant cardiac disease including unstable angina, acute myocardial infarction within six months from Visit 1, congestive heart failure, and arrhythmia requiring therapy, with the exception of extra systoles or minor conduction abnormalities 10. Significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease evaluated by the investigator interfere with effect of the study drug 11. Expected survival < 3 months. 12. Known HIV positive 13. Known active hepatitis B and/or C 14. Screening laboratory values: - WBC < 3.0 x109/L - Neutrophils < 1.5 x109/L - Platelets < 75 x109/L - ALAT > 5 times the upper limit of normal - ALP > 5 times the upper limit of normal (unless known bone metastases) - Bilirubin > 1.5 times the upper limit of normal - Creatinine > 1.5 the upper limit of normal. 15. Current participation in any other interventional clinical study 16. Patients known or suspected of not being able to comply with this trial protocol 17. Breast feeding women or women with a positive pregnancy test at Visit 1. 18. Male not willing to use adequate contraception during and 12 months after last dose of zalutumumab or women of childbearing potential not willing to use adequate contraception as hormonal birth control or intrauterine device, during study and 12 months after last dose of zalutumumab. 19. Patients with known uncontrolled allergic conditions or allergy to the study drugs and/or their components. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Part 1 • Adverse events, clinical laboratory tests and vital signs Part 2 • Objective Response Rate, defined as complete or partial response according to best overall response (verified by imaging technique and according to RECIST criteria).
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |